CDR-Life is recruiting for phase 2 clinical trials of its novel antibody fragment-based therapy for geographic atrophy (GA), following favourable phase 1 safety results.

Engineered using CDR-Life’s proprietary technology and developed by Boehringer Ingelheim, the novel therapy ‘BI 771716’ represents a potential breakthrough in retinal therapy, said Dr Christian Leisner, CDR-Life’s CEO. “Its unique antibody fragment design allows for enhanced penetration across retinal layers to reach key disease targets, (positioning) BI 771716 as a potentially transformative treatment for GA.”